Competitor Analysis: Coagulation Factors
The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 20012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. Projects hvae rapidly progressed in clinical trials and several of them are already under regulatory review.
Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and human plasma-derived products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.
The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific product portoflios and R&D pipelines of coagulation factors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 20012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. Projects hvae rapidly progressed in clinical trials and several of them are already under regulatory review.
Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and human plasma-derived products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.
The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific product portoflios and R&D pipelines of coagulation factors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- Sales of Recombinant Coagulation Factors for Hemophilia in 2012
- Human Plasma-Derived Coagulation Factor VIII Concentrates
- Recombinant Coagulation Factor VIII
- Human Plasma-Derived Coagulation Factor IX
- Recombinant Coagulation Factor IX
- Human Plasma-Derived Factor VII
- Recombinant Coagulation Factor VII
- Human Plasma-Derived Coagulation Factor Concentrates for Willebrand Disease
- Recombinant Human von Willebrand Factor (vWF)
- Human Plasma-Derived Fibrinogen
- Recombinant Human Fibrinogen
- Human Plasma-Derived Factor XI
- Human Plasma-Derived Factor X
- Recombinant Human Factor X
- Human Plasma-Derived Factor XIII
- Recombinant Human Factor XIII
- Alternative Procoagulants & Adjuncts
- Human Plasma-Derived Prothrombin Complex Concentrates
- Gene Therapy of Hemophilia
- Topical Human Plasma-Derived Fibrinogen and Thrombin Products
- Topical Plasma-Derived Thrombin Products
- Topical Recombinant Human Factor II (Prothrombin)
- Alternative Topical Hemostats
- Corporate Coagulation Factor Product Portfolios and R&D Pipelines
